Tsewang Tashi, MD, discusses how elenestinib could be an effective option with a manageable safety profile in ISM.
Understanding the Next Generation of KIT Inhibitors in Indolent Systemic Mastocytosis
Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5